Detalhe da pesquisa
1.
Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety.
Hematol Oncol
; 42(1): e3222, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37740931
2.
Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective.
Xenobiotica
; 53(8-9): 547-558, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37880944
3.
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Blood
; 135(24): 2137-2145, 2020 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32219442
4.
Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
Hematol Oncol
; 40(2): 269-279, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35043428
5.
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Hematol Oncol
; 37(4): 464-473, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31251400
6.
Estimating HIV-1 fitness characteristics from cross-sectional genotype data.
PLoS Comput Biol
; 10(11): e1003886, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25375675
7.
Asia-Inclusive Global Development of Enpatoran: Results of an Ethno-Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial.
Clin Pharmacol Ther
; 115(6): 1346-1357, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38415785
8.
Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies.
Clin Transl Sci
; 15(9): 2075-2095, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35722783
9.
Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials.
Clin Transl Sci
; 15(1): 267-278, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34464029
10.
Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses.
J Clin Pharmacol
; 61(5): 628-635, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33156550
11.
Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia.
Clin Pharmacol Ther
; 109(2): 424-432, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32749675
12.
Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis.
Clin Transl Sci
; 12(6): 625-632, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31268229
13.
Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies.
Clin Pharmacokinet
; 57(11): 1407-1419, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29516428
14.
Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma.
Leuk Lymphoma
; 59(4): 871-879, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28797193
15.
Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies.
Hemasphere
; 7(12): e983, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38026788
16.
Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.
Clin Pharmacokinet
; 56(1): 1-10, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27314261
17.
Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.
Adv Ther
; 33(4): 670-83, 2016 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27084721